These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 19604516)

  • 1. JNK inhibitor protects dopaminergic neurons by reducing COX-2 expression in the MPTP mouse model of subacute Parkinson's disease.
    Wang Y; Zhang Y; Wei Z; Li H; Zhou H; Zhang Z; Zhang Z
    J Neurol Sci; 2009 Oct; 285(1-2):172-7. PubMed ID: 19604516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of phosphorylated c-Jun expression on COX-2 expression in the substantia nigra of MPTP mouse model of subacute Parkinson disease].
    Wang YS; Zhou JP; Wei ZF; Tian QY; Zhou HX; Zhang YX
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Aug; 27(8):1199-202, 1205. PubMed ID: 17715026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta.
    Boyd JD; Jang H; Shepherd KR; Faherty C; Slack S; Jiao Y; Smeyne RJ
    Brain Res; 2007 Oct; 1175():107-16. PubMed ID: 17884023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcumin prevents dopaminergic neuronal death through inhibition of the c-Jun N-terminal kinase pathway.
    Yu S; Zheng W; Xin N; Chi ZH; Wang NQ; Nie YX; Feng WY; Wang ZY
    Rejuvenation Res; 2010 Feb; 13(1):55-64. PubMed ID: 20230279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson's disease.
    Wang W; Shi L; Xie Y; Ma C; Li W; Su X; Huang S; Chen R; Zhu Z; Mao Z; Han Y; Li M
    Neurosci Res; 2004 Feb; 48(2):195-202. PubMed ID: 14741394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    Hayley S; Crocker SJ; Smith PD; Shree T; Jackson-Lewis V; Przedborski S; Mount M; Slack R; Anisman H; Park DS
    J Neurosci; 2004 Feb; 24(8):2045-53. PubMed ID: 14985447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid.
    Karunakaran S; Diwakar L; Saeed U; Agarwal V; Ramakrishnan S; Iyengar S; Ravindranath V
    FASEB J; 2007 Jul; 21(9):2226-36. PubMed ID: 17369508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Zishenpingchan granule prepared from Chinese medicinal substances on the c-Jun N-terminal protein kinase pathway in mice with Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Ye Q; Yuan X; Zhou J; Yuan C; Yang X
    J Tradit Chin Med; 2017 Apr; 37(2):244-51. PubMed ID: 29960635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.
    Saporito MS; Brown EM; Miller MS; Carswell S
    J Pharmacol Exp Ther; 1999 Feb; 288(2):421-7. PubMed ID: 9918541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotective effects of bee venom pharmaceutical acupuncture in acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
    Doo AR; Kim ST; Kim SN; Moon W; Yin CS; Chae Y; Park HK; Lee H; Park HJ
    Neurol Res; 2010 Feb; 32 Suppl 1():88-91. PubMed ID: 20034453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo.
    Saporito MS; Thomas BA; Scott RW
    J Neurochem; 2000 Sep; 75(3):1200-8. PubMed ID: 10936203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effects of 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside in the MPTP-induced mouse model of Parkinson's disease: Involvement of reactive oxygen species-mediated JNK, P38 and mitochondrial pathways.
    He H; Wang S; Tian J; Chen L; Zhang W; Zhao J; Tang H; Zhang X; Chen J
    Eur J Pharmacol; 2015 Nov; 767():175-82. PubMed ID: 26477638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JNK-mediated activation of ATF2 contributes to dopaminergic neurodegeneration in the MPTP mouse model of Parkinson's disease.
    Huang Q; Du X; He X; Yu Q; Hu K; Breitwieser W; Shen Q; Ma S; Li M
    Exp Neurol; 2016 Mar; 277():296-304. PubMed ID: 26515688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease.
    Ghosh A; Roy A; Matras J; Brahmachari S; Gendelman HE; Pahan K
    J Neurosci; 2009 Oct; 29(43):13543-56. PubMed ID: 19864567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease.
    Xia XG; Harding T; Weller M; Bieneman A; Uney JB; Schulz JB
    Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10433-8. PubMed ID: 11504916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
    Shin JY; Park HJ; Ahn YH; Lee PH
    J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible role of propofol's cyclooxygenase-inhibiting property in alleviating dopaminergic neuronal loss in the substantia nigra in an MPTP-induced murine model of Parkinson's disease.
    Kubo K; Inada T; Shingu K
    Brain Res; 2011 Apr; 1387():125-33. PubMed ID: 21376018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective Effects of the DPP4 Inhibitor Vildagliptin in In Vivo and In Vitro Models of Parkinson's Disease.
    Pariyar R; Bastola T; Lee DH; Seo J
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of the c-Jun N terminal kinase pathway in an animal model of Parkinson's disease.
    Willesen MG; Gammeltoft S; Vaudano E
    Ann N Y Acad Sci; 2002 Nov; 973():237-40. PubMed ID: 12485868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease.
    Hunot S; Vila M; Teismann P; Davis RJ; Hirsch EC; Przedborski S; Rakic P; Flavell RA
    Proc Natl Acad Sci U S A; 2004 Jan; 101(2):665-70. PubMed ID: 14704277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.